Pharma Blog Watch
Is
Drug Spending Really a Huge Problem? (DrugWonks.com)
Citing a recent Associated
Press article, blogger Robert Goldberg takes issue with what he views as the all-too-common
journalistic practice of decrying the supposedly "problematic" rise
in drug spending.
Should
GSK's Advair Be Pulled From the Market? (Drug Injury Watch)
A study published
in the Annals of Internal Medicine this month concludes that GlaxoSmithKline's
(GSK) asthma drug Advair could be more dangerous than previously thought
according to the study, the drug could significantly increase the risk of serious
side effects, including death, and should potentially be removed from the market.
Blogger Tom Lamb discusses the details of the study and the problems faced by
GSK in the wake of these new developments.
The
Downside of Licensing Pharma Sales Reps (Pharma Marketing Blog)
An article
in last week's Boston Globe notes than an amendment to the proposed Massachusetts
State Budget could make the state the first in the nation to license pharmaceutical
sales reps and prohibit them from supplying entertainment, gifts and other amenities
to doctors, healthcare facilities or public officials. In his entry, blogger John
Mack questions if licensing these representatives is actually a wise decision.
Upcoming Events
-
28Mar
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May